Sign In
Buy MORF
$56.99
+0 (+0%)
At Close: Nov 14, 2024
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
08:15pm, Wednesday, 29'th Apr 2020
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morph
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
01:12pm, Friday, 10'th Apr 2020
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences
Morphic (NASDAQ:MORF) Lifted to Buy at Zacks Investment Research
09:56am, Thursday, 09'th Apr 2020
Morphic (NASDAQ:MORF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $15.00
Analyzing Horizon Therapeutics (NASDAQ:HZNP) and Morphic (NASDAQ:MORF)
07:32am, Wednesday, 08'th Apr 2020
Horizon Therapeutics (NASDAQ:HZNP) and Morphic (NASDAQ:MORF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
12:00pm, Tuesday, 07'th Apr 2020
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Sc
Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More
09:46am, Friday, 20'th Mar 2020
The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
12:00pm, Tuesday, 17'th Mar 2020
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
01:00pm, Friday, 28'th Feb 2020
WALTHAM, Mass., Feb. 28, 2020 -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the.
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
09:05pm, Thursday, 27'th Feb 2020
WALTHAM, Mass., Feb. 27, 2020 -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro.
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
05:00pm, Wednesday, 08'th Jan 2020
WALTHAM, Mass., Jan. 08, 2020 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
Hedge Funds Are Dumping Morphic Holding, Inc. (MORF)
02:40pm, Saturday, 30'th Nov 2019
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick thei
Morphic to Present at the Jefferies 2019 London Healthcare Conference
09:15pm, Monday, 18'th Nov 2019
WALTHAM, Mass., Nov. 18, 2019 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
09:24pm, Tuesday, 12'th Nov 2019
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by.
Hedge Funds Have Never Been This Bullish On Morphic Holding, Inc. (MORF)
02:35pm, Wednesday, 30'th Oct 2019
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and thes
